PharmaFocus Today – Page 8 – media

Two biosimilars of pembrolizumab have been approved for marketing, and the second indication of Cononospikinumab has been approved

NO.1 Two biosimilars of pertuzumab approved for market launch On December 23rd, the official website of the State Administration for Market Regulation showed that two types of pertuzumab injections were approved for market, one from Qilu Pharmaceutical and the other from Zhengda Tianqing. Patuximab was originally developed by Roche and was first approved for market by the FDA in 2012. It was first approved for market in China in 2018. Currently, multiple indications have been approved worldwide. Comment: Since its approval, the pertuzumab market has performed exceptionally well, with global sales of $4.2 billion in 2023. As a biosimilar drug, it is expected to occupy a certain market share in the original drug market. But currently, there are 7 domestic companies developing drugs similar to pertuzumab, and competition may intensify in the future. NO.2 Kangnuosipuqibai monoclonal antibody second indication approved On December 23rd, Konya announced that its independently developed ...
- Source: drugdu
- 82
- December 25, 2024
ABB’s maintenance plan based on equipment status helps Jiheng Pharmaceutical

Hebei Jiheng Pharmaceutical Co., Ltd. (hereinafter referred to as “Jiheng Pharmaceutical”) has signed a Motion OneCare worry free service agreement with ABB. Through ABB’s remote status monitoring and fault recovery services, the efficiency and quality of wastewater treatment have been improved, and the normal operation time of sewage pumps has been extended, thereby helping the entire pharmaceutical plant to operate smoothly at a larger capacity. Jiheng Pharmaceutical is located in Hengshui City, Hebei Province, about 250 kilometers south of Beijing, China. Its main products include painkillers, vitamin supplements, and pharmaceutical intermediates. Previously, Jiheng Pharmaceutical wanted to improve the reliability of mechanical vapor recompression (MVR) in the application of wastewater pumps driven by ten motors to enhance the stability of the production line. The MVR process can recover and reuse the energy lost during the evaporation process, thereby improving efficiency and saving energy. However, in recent years, unplanned shutdowns have occurred ...
- Source: drugdu
- 70
- December 25, 2024
CR Group’s Big Move – Integration of Two Major Pharmaceutical Companies Completed

01. CR Torch has officially become a subsidiary of Kunming Pharmaceutical Group On December 20-21, CR Sanjiu and Kunming Pharmaceutical Group successively announced the latest progress in the transfer of 51% equity of Kunming CR Torch. On December 20th, the relevant business registration procedures for the transfer of equity of CR Torch were completed. Kunming Pharmaceutical Group holds 51% of the equity of CR Torch, and CR Torch has become a subsidiary of Kunming Pharmaceutical Group and included in its consolidated financial statements. This also means that Kunyao Group, positioned as a leader in the silver hair health industry, has officially taken an important step towards strategic and professional integration of its Sanqi business. Next, Kunyao Group will continue to build itself into a benchmark enterprise in the Sanqi industry chain, further enhancing its market share in the field of cardiovascular and cerebrovascular products. The integration of two major pharmaceutical ...
- Source: drugdu
- 58
- December 25, 2024
CanSino Biologics Launches Phase I/II Clinical Trials for Recombinant Polio Vaccine

Finance China News, December 20 – CanSino Biologics (688185/06185) released a voluntary disclosure announcing that its developed recombinant polio vaccine has initiated Phase I/II clinical trials in Indonesia, with the first subject enrolled in phase I. This vaccine utilizes virus-like particle technology, making it non-infectious, and is expected to perform well in terms of safety and immunogenicity. It is considered one of the preferred vaccines for the future eradication of polio, as recommended by the World Health Organization. This clinical trial will further assess the vaccination safety and immunogenicity of the vaccine in specific age groups of infants and young children. The announcement highlighted the complexity and uncertainty of vaccine development, stressing the unpredictability of the clinical trial process and results, advising investors to make cautious decisions. In the first three quarters of 2024, CanSino achieved revenue of 567 million yuan, with a net profit attributable to the parent company ...
- Source: drugdu
- 88
- December 25, 2024
Zhongshan Pharmaceutical’s “Class 1.1 Chinese Medicine for Gastric Diseases” has been approved for listing

Zhongshan Pharmaceutical’s application for listing of the new Chinese medicine 1.1 “Renshu Jianwei Granules” has been accepted. According to public information, the drug is intended to treat diseases such as atrophic gastritis and precancerous lesions of gastric mucosa. Atrophic gastritis is a disease in which the gastric pits become shallower due to the thinning of the gastric mucosa and the reduction or partial disappearance of intrinsic glands such as acid-secreting glands and mucous glands on the gastric mucosa. According to the degree of gland reduction, atrophic gastritis can be divided into mild, moderate and severe atrophy. Gastric mucosal carcinogenesis is a type of cancer caused by dysplasia of the gastric mucosa. Active treatment and intervention before dysplasia can prevent the occurrence of cancer. Among them, Chinese medicine, as an important category for the treatment of digestive tract and metabolic diseases, also plays a key role in various types of stomach ...
- Source: drugdu
- 88
- December 25, 2024
Latest! “4 innovative medical devices” approved for marketing

Recently, the National Medical Products Administration approved the registration applications for four innovative products: “Intestinal Polyp Electronic Lower Gastrointestinal Endoscopy Image-Assisted Detection Software” by Changsha Huiwei Intelligent Medical Technology Co., Ltd. (hereinafter referred to as Changsha Huiwei Intelligent), “Rotational Ablative Treatment Device” and “Disposable Coronary Ablative Catheter” by Shanghai Microport Melody Medical Technology Co., Ltd. (hereinafter referred to as Microport Melody), and “Disposable Magnetic Electric Positioning Pressure Monitoring Pulsed Electric Field Ablation Catheter” by Hunan Apt Medical Devices Co., Ltd. (hereinafter referred to as Apt Medical). Another product ofChangsha Huiwei Intelligent has been approved Changsha Huiwei Intelligence was established in 2020 and is a wholly-owned subsidiary of Suzhou Huiwei Intelligent Medical Technology Co., Ltd. (hereinafter referred to as Huiwei Intelligence). Huiwei Intelligence was established in June 2019 and specializes in the research and development, production and sales of intelligent medical products. Driven by its independent core technologies in the fields ...
- Source: drugdu
- 59
- December 25, 2024
Everest Medicines/Pfizer’s “autoimmune new drug” is listed in China

On December 17, according to the official website of CDE, Genting New Energy’s application for marketing approval of the Class 5.1 imported chemical drug “Itramod Tablets” was accepted for the treatment of moderate to severe active ulcerative colitis. According to public information, Itramod tablets were originally developed by Arena. Pfizer acquired the company in 2022 and included the drug in its pipeline. Billion-dollar sales prospects target the “million-patient market” Inflammatory bowel disease (IBD) is a type of disease that causes inflammation of the digestive system, and the number of patients worldwide is on the rise. IBD mainly includes ulcerative colitis and Crohn’s disease, of which ulcerative colitis is common in patients aged 20 to 30 years old, and clinical manifestations include persistent or recurrent diarrhea, mucus, pus and blood in the stool with abdominal pain, and even skin lesions and mucosal lesions. At present, the cause of the disease has ...
- Source: drugdu
- 58
- December 25, 2024
Taking advantage of the “Eight Measures of Science and Technology”, Haier Health aims to create a flagship of biotechnology

Query the real-time market situation of the stock, uncover in-depth data on fund flow, and enter Shanghai Laishi Bar. Shanghai Laishi Fund Flow Related Stocks Yongshun Biotechnology (0.000%) Ternary Gene (0.000%) Kangle Defender (0.000%) Oukang Pharmaceutical (0.000%) Related sections Biological products (0.00%) Standard&Poor’s (0.00%) FTSE Russell (0.00%) In vitro diagnostics (0.00%) The first step in stock trading is to open a stock account On the evening of December 22nd, Qingdao Haier Biomedical Co., Ltd. (“Haier Biotech”, 688139. SH) issued a suspension notice regarding the planning of a major asset restructuring. According to the announcement, Haier Biology and Shanghai Laishi Blood Products Co., Ltd. (“Shanghai Laishi”, 002252. SZ) are both listed companies controlled by Haier Group. The two parties have signed an “Absorption and Merger Intention Agreement”, in which Haier Biology will absorb and merge Shanghai Laishi by issuing A-shares to all shareholders of Shanghai Laishi, and raise matching funds through ...
- Source: drugdu
- 130
- December 24, 2024
Beware of “two sets of prices” providing funding sources for pharmaceutical bribery

On December 20th, the National Medical Insurance Bureau sent a letter to the medical insurance bureaus of various provinces, autonomous regions, municipalities directly under the central government, and Xinjiang Production and Construction Corps in response to the investigation of the false invoicing case in the pharmaceutical field by the public security department, requesting a serious investigation into whether there were similar problems with the products involved, such as Ginkgo biloba extract injection, Cefotaxime sodium injection, hydrolyzed protein oral solution, etc., and to quickly determine the bottom line of the listed prices. The National Healthcare Security Administration stated in the letter that it firmly opposes the increase in patient burden caused by inflated drug prices, the formation of illegal profit chains through false invoicing, and illegal and irregular behaviors such as “double pricing of one drug” and “selling with money”. (December 22, People’s Daily Online) Recently, the Economic Reference Daily reported ...
- Source: drugdu
- 191
- December 24, 2024
Is placebo effective? Vertex evaporates $13 billion overnight

On December 19, 2024, Vertex announced that its non opioid painkiller suzetrigine (VX-548) had achieved the primary endpoint of significantly reducing pain in the Phase 2 Sciatica (LSR) study. However, the placebo group also showed significant pain relief (about 2 points), and the difference between the treatment group and the placebo group was not significant. Affected by this news, Vertex’s stock price plummeted by 11.37%. 01. Background VX-548 is a selective NaV1.8 pain signal inhibitor under development, aimed at blocking the transmission of pain signals to the brain by specifically blocking sodium channels in peripheral nerves. Due to its mechanism of action being limited to the peripheral nervous system, VX-548 does not pose an addiction risk to opioid drugs. Previously (December 2023), Vertex retrieved phase 2 clinical data on VX-548 for chronic pain, which showed that its efficacy was comparable to that of the control group Pregabalin. This study further ...
- Source: drugdu
- 117
- December 24, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.